Handa Pharmaceuticals Past Earnings Performance
Past criteria checks 4/6
Handa Pharmaceuticals has been growing earnings at an average annual rate of 50.2%, while the Pharmaceuticals industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 65.5% per year. Handa Pharmaceuticals's return on equity is 26.4%, and it has net margins of 65.7%.
Key information
50.2%
Earnings growth rate
49.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 18.5% |
| Revenue growth rate | 65.5% |
| Return on equity | 26.4% |
| Net Margin | 65.7% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Handa Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1,106 | 727 | 105 | 307 |
| 30 Sep 23 | 956 | 707 | 91 | 275 |
| 30 Jun 23 | 723 | 540 | 89 | 208 |
| 31 Mar 23 | 460 | 250 | 86 | 196 |
| 31 Dec 22 | 198 | -40 | 87 | 180 |
| 30 Sep 22 | 56 | -173 | 78 | 183 |
| 30 Jun 22 | 56 | -217 | 75 | 204 |
| 31 Mar 22 | 43 | -233 | 74 | 206 |
| 31 Dec 21 | 29 | -248 | 73 | 209 |
| 30 Sep 21 | 29 | -250 | 72 | 227 |
| 30 Jun 21 | 29 | -253 | 72 | 245 |
| 31 Mar 21 | 29 | -268 | 71 | 259 |
| 31 Dec 20 | 29 | -282 | 71 | 274 |
| 30 Sep 20 | 34 | -273 | 83 | 250 |
| 30 Jun 20 | 38 | -263 | 95 | 226 |
| 31 Mar 20 | 61 | -220 | 97 | 200 |
| 31 Dec 19 | 84 | -178 | 99 | 174 |
| 30 Sep 19 | 93 | -160 | 90 | 173 |
| 30 Jun 19 | 103 | -141 | 80 | 172 |
| 31 Mar 19 | 98 | -154 | 82 | 169 |
| 31 Dec 18 | 94 | -167 | 83 | 166 |
| 30 Sep 18 | 81 | -167 | 83 | 158 |
| 30 Jun 18 | 69 | -167 | 82 | 149 |
| 31 Mar 18 | 303 | 63 | 82 | 150 |
| 31 Dec 17 | 538 | 293 | 82 | 150 |
| 30 Sep 17 | 620 | 368 | 84 | 145 |
| 30 Jun 17 | 702 | 442 | 87 | 140 |
| 31 Mar 17 | 457 | 235 | 81 | 125 |
| 31 Dec 16 | 211 | 29 | 75 | 109 |
| 30 Sep 16 | 119 | -43 | 65 | 100 |
| 30 Jun 16 | 28 | -115 | 55 | 91 |
| 31 Mar 16 | 14 | -121 | 49 | 85 |
| 31 Dec 15 | 0 | -128 | 42 | 79 |
| 31 Dec 14 | 3 | -17 | 3 | 16 |
Quality Earnings: 6620 has high quality earnings.
Growing Profit Margin: 6620 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6620 has become profitable over the past 5 years, growing earnings by 50.2% per year.
Accelerating Growth: 6620 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 6620 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-15%).
Return on Equity
High ROE: 6620's Return on Equity (26.4%) is considered high.